Large gap with delayed quotes
|
Last quote
11/04/2025
-
02:00:00
|
Bid
11/04/2025 -
12:35:01
|
Bid Volume |
Ask
11/04/2025 -
12:35:01
|
Ask Volume |
|---|---|---|---|---|
|
412.35
-6.55
(
-1.56% )
|
400.00
|
40 |
475.00
|
40 |
Analysis date: 31.10.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 30.09.2025.
Interest
Strong
Strong
Three stars since 24.10.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 24.10.2025 at a price of 421.50.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 05.08.2025.
4wk Rel Perf
-10.94%
-10.94%
The four-week dividend-adjusted underperformance versus SP500 is 10.94%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.16%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.83%.
Mkt Cap in $bn
9.34
9.34
With a market capitalization >$8bn, MADRIGAL PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
11.61
11.61
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
13.31
13.31
The estimated PE is for the year 2027.
LT Growth
154.51%
154.51%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
88
88
For 1% of index variation, the stock varies on average by 0.88%.
Correlation
0.33
0.33
Stock movements are strongly independent of index variations.
Value at Risk
101.13
101.13
The value at risk is estimated at USD 101.13. The risk is therefore 24.14%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.07.2018
27.07.2018